The use of sirolimus in ganciclovir‐resistant cytomegalovirus infections in renal transplant recipients

• DOI: 10.1111/j.1399-0012.2007.00699.x
• Publication Date: 2007-05-09T04:32:33Z
• Authors: Kikumi Suzete Ozaki; Niels Olsen Sarai...; Eliana Nogueira; Mauricio Galvão P...; Celso Granato; Cláudio Melaragno; Luis Fernando Ara...; Alvaro Pacheco‐Silva
• Keywords: Sirolimus; Cytomegalovirus; Betaherpesvirinae; Foscarnet; Valaciclovir; Immunosuppression

Abstract: Background: The widespread use of prophylactic ganciclovir and anti‐lymphocyte/thymocyte therapies are associated with increased induction ganciclovir‐resistant cytomegalovirus (CMV) strains. sirolimus has been a lower incidence CMV infection in transplant recipients. We questioned whether it could also be effective as therapeutic treatment resistant infection. Methods: Patients infections determined clinically by DNA sequencing analysis were enrolled. Antigenaemia used to diagnosis follow the mutations. Results: Nine patients given plus mycophenolate mofetil (n = 4) or calcineurin inhibitor 5). Seven out nine recipients IgG negative before transplantation. observed rapid decrease antigenaemia levels, reaching zero eight (88.9%) within median 20.3 ± 10.1 d. Graft function remained stable no patient presented acute rejection recurrence Conclusions: This suggests that therapy useful infections.